Why America’s biggest charities are owned by pharmaceutical companies

The Economist

13 August 2019 - Their generosity helps their bottom line.

When patients in need of medicines in America go to fill their prescription the price they have to pay can vary wildly. For generic off-patent drugs prices are usually low for the uninsured and free for those with insurance. But for newer patent-protected therapies prices can be as high as several thousand dollars per month. 

Those without insurance might end up facing these lofty list prices. Even those with coverage will often have to fork out some of the cost, called a co-payment, while their insurance covers the rest.

Read The Economist article

Michael Wonder

Posted by:

Michael Wonder